Arcade Therapeutics and Kean University Offer Game-Based Digital Therapeutic to College Students with Social Anxiety

Arcade and Kean will launch a separate research study to investigate the impact of StarStarter Rx on student mental health. Arcade Therapeutics jointly announced a partnership with Kean University’s Counseling Center to offer students StarStarter Rx, a therapeutic mobile game designed to reduce social anxiety. Kean will offer free access to Arcade’s digital therapeutic as part of a broader initiative to expand its facilities and mental health resources. “Social anxiety can be debilitating to students’ lives by encouraging avoidant behavior through excessive rumination and worry. It can be the obstacle to joining an extracurricular activity, having fun with friends, or raising your hand in class…

Arcade Therapeutics and UT Austin Jointly Announce a $3.8M NIMH Grant to Fund Large Clinical Trial Testing the Efficacy of ABM-02, The First Game-Based Digital Therapeutic for Major Depressive Disorder

The R01 Grant from the National Institute of Health, consisting of $3.8M in funding to UT Austin’s Institute for Mental Health Research, was recently approved with a kickoff date of September 1st. Arcade Therapeutics and University of Texas Austin’s Institute for Mental Health Research jointly announced the closing of a $3.8M grant from the National Institute for Mental Health (NIMH) to support clinical investigation and validation of ABM-02 as a game-based treatment for Major Depressive Disorder (MDD)…

Clinical Trial of Arcade Therapeutics’ Flagship Therapeutic Mobile Game, StarStarter Rx, Shows Robust Reductions in Social Anxiety in Adults

Arcade Therapeutics (fka Wise Therapeutics) announced topline results of their StarStarter Rx Pilot Study, evaluating the efficacy and safety of their flagship digital therapeutic in adults 22-65 with Social Anxiety Disorder (SAD). The study achieved its predefined efficacy outcome for its primary endpoint, the Liebowitz Social Anxiety Scale (LSAS), as well as secondary and exploratory outcome measures such as the Beck Depression Inventory (BDI-II)…

Wise Therapeutics Announces Healthcare Provider Integrated Deployments to Serve Critical Need for More Accessible Mental Health Treatments

Wise Connect™ Platform offers integrated HIPAA-compliant solution for deployment of digital therapeutics to patients (APRIL 6, 2022, NEW YORK) Wise Therapeutics (Wise), a leading developer of game-based digital therapeutics for mental health, announced new deployments of their digital therapeutics across a variety of healthcare settings, ranging from therapy practices to large health systems. These deployments were enabled by the launch of

Read More

Wise Therapeutics and Soterix Medical Jointly Announce Positive Results of Study Combining Gamified Digital Therapeutics with Neurostimulation Device

Partnership demonstrates how at-home transcranial direct current stimulation (tDCS) can enhance the clinical impact of Wise’s gamified digital therapeutics (June 30, 2021, NEW YORK) Wise Therapeutics (Wise), a developer of game-based digital therapeutics including Personal Zen, and Soterix Medical, a leading manufacturer of wearable tDCS medical devices, jointly announced the results of their collaborative study, published in Frontiers in Neuroergonomics. The study demonstrates how neurostimulation

Read More